Neutropenia — Low White Blood Cell Counts in Oncology

Neutropenia is formally defined as an absolute neutrophil count (ANC) falling below established laboratory thresholds, typically fewer than 1,500 cells per microlitre of blood in adults. Severity is graded clinically: mild (ANC 1,000–1,500 cells/µL), moderate (ANC 500–1,000 cells/µL), and severe (ANC less than 500 cells/µL), with severe neutropenia conferring the greatest risk of acute systemic infection.

In oncology, neutropenia most frequently stems from chemotherapy-induced bone marrow suppression. Cytotoxic agents target rapidly proliferating cells, inadvertently depleting haematopoietic progenitor cells within the bone marrow. When production ceases temporarily, circulating neutrophils deplete rapidly due to their short natural lifespan of only several hours to a few days, creating a vulnerable window known as the nadir.

Neutropenia is one of the most critical safety considerations during active cancer therapy. If an infection occurs while neutrophils are severely low—a condition known as febrile neutropenia—it constitutes an oncological emergency requiring urgent hospital evaluation and intravenous antibiotics. Furthermore, prolonged neutropenia can lead to treatment delays or dose reductions, which may compromise the overall momentum of cancer eradication if supportive measures are not implemented.

Neutropenia is identified through a routine blood test called a full blood count with differential. This test measures the total white blood cell count and calculates the Absolute Neutrophil Count (ANC). During active chemotherapy cycles, blood counts are checked periodically, particularly around the expected nadir (usually seven to fourteen days post-infusion), to verify immune recovery before the next treatment cycle.

Neutropenia can develop across virtually any cancer treated with systemic cytotoxic chemotherapy. It is exceptionally common in haematological cancers such as acute myeloid leukaemia, acute lymphoblastic leukaemia, and high-grade lymphomas, where the bone marrow is heavily involved. It also frequently occurs during intensive regimens for breast, ovarian, lung, and gastrointestinal malignancies.

When neutropenia is expected or occurs, oncologists may administer granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim, to stimulate bone marrow production of white blood cells. If a patient develops a fever during neutropenia, immediate broad-spectrum intravenous antibiotics are initiated. Depending on the duration and depth of the low count, subsequent chemotherapy doses may be adjusted or temporarily delayed.